Patricia Smawley
Nurse Practitioner · Prince Frederick, MDNPI 1770109456
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$480
- Supernus Pharmaceuticals, Inc.$455
- AstraZeneca$294
- Amgen$289
- Merck$288
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,187100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 81 | $1,056 |
| Novo Nordisk | 23 | $480 |
| Supernus Pharmaceuticals, Inc. | 50 | $455 |
| AstraZeneca(2 entities) | 14 | $294 |
| Amgen(2 entities) | 13 | $289 |
| Merck | 16 | $288 |
| Pfizer | 15 | $275 |
| Bayer | 6 | $252 |
| Esperion Therapeutics, Inc. | 7 | $219 |
| GSK | 9 | $215 |
| Lilly USA, LLC | 9 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $147 |
| Exact Sciences | 5 | $120 |
| Boehringer Ingelheim | 5 | $101 |
| Cranial Technologies, Inc | 7 | $100 |
| Boston Scientific | 1 | $98 |
| Axsome Therapeutics, Inc. | 3 | $86 |
| Sanofi Pasteur Inc. | 3 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Hologic Sales And Service, LLC | 2 | $55 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Novartis | 2 | $42 |
| Seqirus USA Inc | 2 | $39 |
| Sobi, Inc | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Medtronic | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Cognoa, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,187 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 23 | $46,090 |
| JardianceEmpagliflozin | 29 | $42,730 |
| FarxigaDapagliflozin Propanediol | 17 | $17,524 |
| Atorvastatin Calcium | 135 | $1,575 |
| Rosuvastatin Calcium | 99 | $1,436 |
| Trazodone Hcl | 37 | $1,288 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 32 | $921 |
| Losartan Potassium | 51 | $819 |
| Metoprolol Succinate | 50 | $737 |
| Pantoprazole Sodium | 30 | $645 |
| Ezetimibe | 17 | $644 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $615 |
| Metformin Hcl ErMetformin Hcl | 38 | $431 |
| Amlodipine Besylate | 76 | $406 |
| Escitalopram Oxalate | 13 | $354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $480 | $46,09023 claims |
| Boehringer IngelheimJardiance | $101 | $42,73029 claims |
| AstraZenecaFarxiga | $294 | $17,52417 claims |
| AbbVieSynthroid | $1,056 | $19011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,562 nurse practitioner providers in Maryland.
Other nurse practitioner in Prince Frederick
- Morgan GaleRockville$292K
- Sherilyn BrinkleyBaltimore$100K
- Michelle TurnerBaltimore$94K
- Nelli ZafmanLutherville$67K
- Ellen LancasterFallston$52K
- Doris TateEaston$34K
- Zeev NemirovskyBaltimore$19K
- Martha ReilleyAnnapolis$18K
- Stephanie ZwonitzerAnnapolis$16K
- Jennifer MaglianoTimonium$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.